Evidence map›Paper›PMID 19013003›Full record

ArticleExperimental hematology2009

Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH.

William J Savage, James P Barber, Galina L Mukhina, Rong Hu, Guibin Chen, William Matsui, Chris Thoburn, Allan D Hess, Linzhao Cheng, Richard J Jones and 1 more

Open access · greenAbstract read
In one paragraph

Article in Experimental hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Clonal hematopoiesis and bone marrow failure syndromes.Best practice & research. Clinical haematology · 2021
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Morphological Spectrum of Paroxysmal Nocturnal Hemoglobinuria (PNH).Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2015
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

William J SavageDivision of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA.
James P Barber
Galina L Mukhina
Rong Hu
Guibin Chen
William Matsui
Chris Thoburn
Allan D Hess
Linzhao Cheng
Richard J Jones
Robert A Brodsky
Sidney Kimmel Comprehensive Cancer Center · USJohns Hopkins Medicine · USJohns Hopkins University · US

Funding

TUMOR VACCINESP01CA015396 · NCI · JOHNS HOPKINS UNIVERSITY · PI HESS, ALLAN D · 1985 to 2016
$38.1M
THERAPEUTIC USE OF STEM CELLSP01CA070970 · NCI · JOHNS HOPKINS UNIVERSITY · PI CIVIN, CURT I · 1998 to 2012
$23.7M
Human embryonic stem (ES) and embroyonic germ (EG) cells to blood and immune cellR01HL073781 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CHENG, LINZHAO · 2003 to 2013
$4.2M
NCI NIH HHS CA15396NCI NIH HHS CA70970NCI NIH HHS P01 CA015396NCI NIH HHS P01 CA070970NHLBI NIH HHS HL073781
6 · The paper itself

Abstract

objectiveInvestigate the contribution of PIG-A mutations to clonal expansion in paroxysmal nocturnal hemoglobinuria (PNH). MATERIALS AND

methodsPrimary CD34+ hematopoietic progenitors from PNH patients were assayed for annexin-V positivity by flow cytometry in a cell-mediated killing assay using autologous effectors from PNH patients or allogeneic effectors from healthy controls. To specifically assess the role of the PIG-A mutation in the development of clonal dominance and address confounders of secondary mutation and differential immune attack that can confound experiments using primary cells, we established an inducible PIG-A CD34+ myeloid cell line, TF-1. Apoptosis resistance was assessed after exposure to allogeneic effectors, NK92 cells (an interleukin-2-dependent cell line with the phenotype and function of activated natural killer [NK] cells), tumor necrosis factor (TNF)-alpha, and gamma-irradiation. Apoptosis was measured by annexin-V staining and caspase 3/7 activity.

resultsIn PNH patients, CD34+ hematopoietic progenitors lacking glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-AP(-)) were less susceptible than GPI-AP+ CD34+ precursors to autologous (8% vs 49%; p < 0.05) and allogeneic (28% vs 58%; p < 0.05) cell-mediated killing from the same patients. In the inducible PIG-A model, GPI-AP(-) TF-1 cells exhibited less apoptosis than induced, GPI-AP+ TF-1 cells in response to allogeneic cell-mediated killing, NK92-mediated killing, TNF-alpha, and gamma-irradiation. GPI-AP(-) TF-1 cells maintained resistance to apoptosis when effectors were raised against GPI-AP(-) cells, arguing against a GPI-AP being the target of immune attack in PNH. NK92-mediated killing was partially inhibited with blockade by specific antibodies to the stress-inducible GPI-AP ULBP1 and ULBP2 that activate immune effectors. Clonal competition experiments demonstrate that the mutant clone expands over time under proapoptotic conditions with TNF-alpha.

conclusionPIG-A mutations contribute to clonal expansion in PNH by conferring a survival advantage to hematopoietic progenitors under proapoptotic stresses.

Indexed as

ApoptosisAdultAnnexin A5Caspase 3Caspase 7Cell LineFemaleGamma RaysHematopoietic Stem CellsHemoglobinuria, ParoxysmalHumansMaleMembrane ProteinsMiddle AgedMutationTumor Necrosis Factor-alphaAnnexin A5CASP3 protein, humanCaspase 3Caspase 7Membrane Proteinsphosphatidylinositol glycan-class A proteinTumor Necrosis Factor-alpha

Identifiers

PMID19013003
PMCPMC2628761
OpenAlexW1997029811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.